Titus J Boggon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8551569/publications.pdf

Version: 2024-02-01

130 papers	29,521 citations	25034 57 h-index	14208 128 g-index
132 all docs	132 docs citations	132 times ranked	34190 citing authors

#	Article	IF	Citations
1	Tousled-like kinase 2 targets ASF1 histone chaperones through client mimicry. Nature Communications, 2022, 13, 749.	12.8	9
2	Lyso-PAF, a biologically inactive phospholipid, contributes to RAF1 activation. Molecular Cell, 2022, 82, 1992-2005.e9.	9.7	5
3	Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients. Journal of Experimental Medicine, 2021, 218, .	8.5	31
4	Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity. Blood, 2021, 138, 1225-1236.	1.4	49
5	Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1. Nature Communications, 2021, 12, 4960.	12.8	32
6	Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Molecular Cell, 2021, 81, 3833-3847.e11.	9.7	10
7	The pseudoGTPase group of pseudoenzymes. FEBS Journal, 2020, 287, 4232-4245.	4.7	14
8	The GTPase-activating protein p120RasGAP has an evolutionarily conserved â€œFLVR-uniqueâ€•SH2 domain. Journal of Biological Chemistry, 2020, 295, 10511-10521.	3.4	8
9	Recognition of physiological phosphorylation sites by p21-activated kinase 4. Journal of Structural Biology, 2020, 211, 107553.	2.8	7
10	SH2 Domain Binding: Diverse FLVRs of Partnership. Frontiers in Endocrinology, 2020, 11, 575220.	3.5	20
11	Crystallographic Studies of the Cerebral Cavernous Malformations Proteins. Methods in Molecular Biology, 2020, 2152, 291-302.	0.9	1
12	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22730-22736.	7.1	52
13	Î³-6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A. Molecular Cell, 2019, 76, 857-871.e9.	9.7	39
14	Clamping Together Hemidesmosomes and Latching Them in Place. Structure, 2019, 27, 881-883.	3.3	1
15	Comprehensive profiling of the STE20 kinase family defines features essential for selective substrate targeting and signaling output. PLoS Biology, 2019, 17, e2006540.	5.6	41
16	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Cancer Discovery, 2019, 9, 756-777.	9.4	18
17	ARGuing for a new kinase class. Nature Chemical Biology, 2019, 15, 431-432.	8.0	0
18	Mutations in ILK, encoding integrin-linked kinase, are associated with arrhythmogenic cardiomyopathy. Translational Research, 2019, 208, 15-29.	5.0	33

#	Article	IF	Citations
19	Mutations in TFAP2B and previously unimplicated genes of the BMP, Wnt, and Hedgehog pathways in syndromic craniosynostosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15116-15121.	7.1	24
20	Crystal structures of p120RasGAP N-terminal SH2 domain in its apo form and in complex with a p190RhoGAP phosphotyrosine peptide. PLoS ONE, 2019, 14, e0226113.	2.5	13
21	CDC42 binds PAK4 via an extended GTPase-effector interface. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 531-536.	7.1	29
22	PAK4 crystal structures suggest unusual kinase conformational movements. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2018, 1866, 356-365.	2.3	11
23	The crystal structure of pseudokinase PEAK1 (Sugen kinase 269) reveals an unusual catalytic cleft and a novel mode of kinase fold dimerization. Journal of Biological Chemistry, 2018, 293, 1642-1650.	3.4	42
24	The N-Terminal GTPase Domain of p190RhoGAP Proteins Is a PseudoGTPase. Structure, 2018, 26, 1451-1461.e4.	3.3	10
25	PseudoGTPase domains in p190RhoGAP proteins: a mini-review. Biochemical Society Transactions, 2018, 46, 1713-1720.	3.4	7
26	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell, 2018, 34, 315-330.e7.	16.8	94
27	Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin. Oncogene, 2017, 36, 254-262.	5.9	53
28	p190RhoGAP proteins contain pseudoGTPase domains. Nature Communications, 2017, 8, 506.	12.8	21
29	The repeat region of cortactin is intrinsically disordered in solution. Scientific Reports, 2017, 7, 16696.	3.3	9
30	Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood, 2017, 130, 1430-1440.	1.4	131
31	PAK6 targets to cell-cell adhesions via its N-terminus in a Cdc42-dependent manner to drive epithelial colony escape. Journal of Cell Science, 2016, 129, 380-93.	2.0	23
32	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension. Hepatology, 2016, 63, 1977-1986.	7.3	46
33	Structural Basis for Noncanonical Substrate Recognition of Cofilin/ADF Proteins by LIM Kinases. Molecular Cell, 2016, 62, 397-408.	9.7	44
34	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelialâ€“mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12238-12243.	7.1	181
35	Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. Molecular Cell, 2016, 64, 859-874.	9.7	73
36	Data publication with the structural biology data grid supports live analysis. Nature Communications, 2016, 7, 10882.	12.8	113

#	Article	IF	Citations
37	Signaling, Regulation, and Specificity of the Type II p21-activated Kinases. Journal of Biological Chemistry, 2015, 290, 12975-12983.	3.4	51
38	Glutamate Dehydrogenase 1 Signals through Antioxidant Glutathione Peroxidase 1 to Regulate Redox Homeostasis and Tumor Growth. Cancer Cell, 2015, 27, 257-270.	16.8	269
39	The Strength and Cooperativity of KIT Ectodomain Contacts Determine Normal Ligand-Dependent Stimulation or Oncogenic Activation in Cancer. Molecular Cell, 2015, 57, 191-201.	9.7	26
40	Structural Basis for the Disruption of the Cerebral Cavernous Malformations 2 (CCM2) Interaction with Krev Interaction Trapped 1 (KRIT1) by Disease-associated Mutations. Journal of Biological Chemistry, 2015, 290, 2842-2853.	3.4	37
41	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular Cell, 2015, 59, 345-358.	9.7	125
42	Genomic landscape of cutaneous T cell lymphoma. Nature Genetics, 2015, 47, 1011-1019.	21.4	347
43	AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis. Cancer Research, 2015, 75, 3492-3504.	0.9	14
44	Structure of the ABL2/ARG kinase in complex with dasatinib. Acta Crystallographica Section F, Structural Biology Communications, 2015, 71, 443-448.	0.8	7
45	CCM2â€“CCM3 interaction stabilizes their protein expression and permits endothelial network formation. Journal of Cell Biology, 2015, 208, 987-1001.	5.2	46
46	Structural analysis of the KRIT1 ankyrin repeat and FERM domains reveals a conformationally stable ARDâ€“FERM interface. Journal of Structural Biology, 2015, 192, 449-456.	2.8	12
47	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1â€“AMPK signalling. Nature Cell Biology, 2015, 17, 1484-1496.	10.3	224
48	Structure and vascular function of MEKK3â€“cerebral cavernous malformations 2 complex. Nature Communications, 2015, 6, 7937.	12.8	69
49	Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative. Blood, 2015, 126, 87-87.	1.4	19
50	The cerebral cavernous malformations proteins. Oncotarget, 2015, 6, 32279-32280.	1.8	8
51	Cerebral cavernous malformation proteins at a glance. Journal of Cell Science, 2014, 127, 701-7.	2.0	89
52	Tyr-301 Phosphorylation Inhibits Pyruvate Dehydrogenase by Blocking Substrate Binding and Promotes the Warburg Effect. Journal of Biological Chemistry, 2014, 289, 26533-26541.	3.4	61
53	Identification of <scp>PLX</scp>4032â€resistance mechanisms and implications for novel <scp>RAF</scp> inhibitors. Pigment Cell and Melanoma Research, 2014, 27, 253-262.	3.3	44
54	Two Amino Acid Residues Confer Different Binding Affinities of Abelson Family Kinase Src Homology 2 Domains for Phosphorylated Cortactin. Journal of Biological Chemistry, 2014, 289, 19704-19713.	3.4	12

#	Article	IF	Citations
55	Tyr-94 Phosphorylation Inhibits Pyruvate Dehydrogenase Phosphatase 1 and Promotes Tumor Growth. Journal of Biological Chemistry, 2014, 289, 21413-21422.	3.4	50
56	Structural Determinants for Binding of Sorting Nexin 17 (SNX17) to the Cytoplasmic Adaptor Protein Krev Interaction Trapped 1 (KRIT1). Journal of Biological Chemistry, 2014, 289, 25362-25373.	3.4	23
57	Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology. Cellular and Molecular Life Sciences, 2014, 71, 1881-1892.	5.4	67
58	Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex. Molecular Cell, 2014, 53, 534-548.	9.7	247
59	Differential binding to the ILK complex determines kindlin isoform adhesion localization and integrin activation. Journal of Cell Science, 2014, 127, 4308-21.	2.0	60
60	Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nature Genetics, 2014, 46, 1135-1139.	21.4	417
61	Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth. Molecular Cell, 2014, 55, 552-565.	9.7	107
62	Global Analysis of Human Nonreceptor Tyrosine Kinase Specificity Using High-Density Peptide Microarrays. Journal of Proteome Research, 2014, 13, 4339-4346.	3.7	42
63	Identification of a Major Determinant for Serine-Threonine Kinase Phosphoacceptor Specificity. Molecular Cell, 2014, 53, 140-147.	9.7	91
64	Structural studies of cerebral cavernous malformations 2 (CCM2) reveal a folded helical domain at its Câ€terminus. FEBS Letters, 2013, 587, 272-277.	2.8	35
65	Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17832-17837.	7.1	25
66	A Network of Interactions Enables CCM3 and STK24 to Coordinate UNC13D-Driven Vesicle Exocytosis in Neutrophils. Developmental Cell, 2013, 27, 215-226.	7.0	70
67	Mineralocorticoid Receptor Phosphorylation Regulates Ligand Binding and Renal Response to Volume Depletion and Hyperkalemia. Cell Metabolism, 2013, 18, 660-671.	16.2	152
68	Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition. Journal of Structural Biology, 2013, 181, 243-251.	2.8	13
69	Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2916-2921.	7.1	275
70	Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3489-3494.	7.1	144
71	Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nature Communications, 2013, 4, 1790.	12.8	75
72	Mechanism for KRIT1 Release of ICAP1-Mediated Suppression of Integrin Activation. Molecular Cell, 2013, 49, 719-729.	9.7	76

#	Article	IF	Citations
73	p90 RSK2 Mediates Antianoikis Signals by both Transcription-Dependent and -Independent Mechanisms. Molecular and Cellular Biology, 2013, 33, 2574-2585.	2.3	28
74	Cocrystal structure of the ICAP1 PTB domain in complex with a KRIT1 peptide. Acta Crystallographica Section F: Structural Biology Communications, 2013, 69, 494-498.	0.7	11
75	<scp>MERTK</scp> controls melanoma cell migration and survival and differentially regulates cell behavior relative to <scp>AXL</scp>. Pigment Cell and Melanoma Research, 2013, 26, 527-541.	3.3	44
76	RAC1 ^{P29S} is a spontaneously activating cancer-associated GTPase. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 912-917.	7.1	146
77	Substrate and Inhibitor Specificity of the Type II p21-Activated Kinase, PAK6. PLoS ONE, 2013, 8, e77818.	2.5	19
78	Purification and SAXS Analysis of the Integrin Linked Kinase, PINCH, Parvin (IPP) Heterotrimeric Complex. PLoS ONE, 2013, 8, e55591.	2.5	12
79	SHP Family Protein Tyrosine Phosphatases Adopt Canonical Active-Site Conformations in the Apo and Phosphate-Bound States. Protein and Peptide Letters, 2013, 20, 1039-1048.	0.9	7
80	Structural Basis for Paxillin Binding and Focal Adhesion Targeting of Î²-Parvin. Journal of Biological Chemistry, 2012, 287, 32566-32577.	3.4	33
81	Calcium-induced Conformational Changes in C-terminal Tail of Polycystin-2 Are Necessary for Channel Gating. Journal of Biological Chemistry, 2012, 287, 17232-17240.	3.4	45
82	Structural Basis for Small G Protein Effector Interaction of Ras-related Protein 1 (Rap1) and Adaptor Protein Krev Interaction Trapped 1 (KRIT1). Journal of Biological Chemistry, 2012, 287, 22317-22327.	3.4	46
83	Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16107-16112.	7.1	73
84	Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth. Cancer Cell, 2012, 22, 585-600.	16.8	329
85	Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics, 2012, 44, 1006-1014.	21.4	1,052
86	Lysozyme contamination facilitates crystallization of a heterotrimeric cortactinâ€“Argâ€“lysozyme complex. Acta Crystallographica Section F: Structural Biology Communications, 2012, 68, 154-158.	0.7	11
87	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics, 2012, 44, 852-860.	21.4	1,049
88	Phosphoglycerate Mutase 1 Promotes Leukemia Metabolism by Coordinating Glycolysis and Biosynthesis, and Represnts a Therapuetic Target in Leukemia Treatment. Blood, 2012, 120, 860-860.	1.4	1
89	Tyrosine Phosphorylation of Mitochondrial Pyruvate Dehydrogenase Kinase 1 Is Important for Cancer Metabolism. Molecular Cell, 2011, 44, 864-877.	9.7	278
90	The Use of Structural Biology in Janus Kinase Targeted Drug Discovery. Current Drug Targets, 2011, 12, 546-555.	2.1	49

#	Article	IF	Citations
91	Molecular Recognition of Leucine-Aspartate Repeat (LD) Motifs by the Focal Adhesion Targeting Homology Domain of Cerebral Cavernous Malformation 3 (CCM3). Journal of Biological Chemistry, 2011, 286, 26138-26147.	3.4	35
92	Tyrosine Phosphorylation of Lactate Dehydrogenase A Is Important for NADH/NAD⁺ Redox Homeostasis in Cancer Cells. Molecular and Cellular Biology, 2011, 31, 4938-4950.	2.3	193
93	EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget, 2010, 1, 497-514.	1.8	159
94	Structure of the EF-hand domain of polycystin-2 suggests a mechanism for Ca ²⁺ -dependent regulation of polycystin-2 channel activity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9176-9181.	7.1	78
95	Crystal Structure of CCM3, a Cerebral Cavernous Malformation Protein Critical for Vascular Integrity. Journal of Biological Chemistry, 2010, 285, 24099-24107.	3.4	75
96	Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2866-2871.	7.1	66
97	Stabilization of VEGFR2 Signaling by Cerebral Cavernous Malformation 3 Is Critical for Vascular Development. Science Signaling, 2010, 3, ra26.	3.6	148
98	Structural basis of competition between PINCH1 and PINCH2 for binding to the ankyrin repeat domain of integrin-linked kinase. Journal of Structural Biology, 2010, 170, 157-163.	2.8	19
99	Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth. Blood, 2010, 116, 3142-3142.	1.4	0
100	Genetic Abnormalities of the EGFR Pathway in African American Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 5620-5626.	1.6	85
101	Analysis of the cytoplasmic interaction between polycystin-1 and polycystin-2. American Journal of Physiology - Renal Physiology, 2009, 297, F1310-F1315.	2.7	30
102	Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation. Molecular and Cellular Biology, 2009, 29, 2105-2117.	2.3	53
103	Disruption of the EGFR E884â€“R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene, 2009, 28, 518-533.	5.9	17
104	JAK3: A two-faced player in hematological disorders. International Journal of Biochemistry and Cell Biology, 2009, 41, 2376-2379.	2.8	76
105	Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth. Science Signaling, 2009, 2, ra73.	3.6	632
106	Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer. Journal of Clinical Oncology, 2008, 26, 1742-1751.	1.6	267
107	Domain Mapping of the Polycystin-2 C-terminal Tail Using de Novo Molecular Modeling and Biophysical Analysis. Journal of Biological Chemistry, 2008, 283, 28305-28312.	3.4	69
108	The structural basis of integrin-linked kinaseâ€“PINCH interactions. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20677-20682.	7.1	74

#	Article	IF	Citations
109	Structural and numerical variation of FLT3/ITD in pediatric AML. Blood, 2008, 111, 4930-4933.	1.4	86
110	BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations. PLoS Medicine, 2007, 4, e315.	8.4	444
111	Automated Protein Crystallization Trials Using the Thermo Scientific Matrix Hydra II eDrop. Journal of the Association for Laboratory Automation, 2007, 12, 213-218.	2.8	7
112	Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies. Cancer Research, 2007, 67, 10417-10427.	0.9	63
113	Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity. Cancer Cell, 2007, 11, 217-227.	16.8	933
114	Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles. Cancer Cell, 2007, 12, 501-513.	16.8	174
115	Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles.. Blood, 2007, 110, 206-206.	1.4	2
116	JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood, 2006, 108, 2770-2779.	1.4	104
117	Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell, 2006, 10, 65-75.	16.8	295
118	Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood, 2005, 106, 996-1002.	1.4	158
119	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7, 387-397.	16.8	2,695
120	EGFRMutation and Resistance of Nonâ€“Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 2005, 352, 786-792.	27.0	3,715
121	Jak3 Kinase Domain Crystal Structures and Implications for Jak-Specific Drug Design.. Blood, 2005, 106, 69-69.	1.4	3
122	Structure and regulation of Src family kinases. Oncogene, 2004, 23, 7918-7927.	5.9	588
123	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 2004, 304, 1497-1500.	12.6	9,038
124	Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood, 2004, 104, 1855-1858.	1.4	80
125	Apocrustacyanin C1crystals grown in space and on earth using vapour-diffusion geometry: protein structure refinements and electron-density map comparisons. Acta Crystallographica Section D: Biological Crystallography, 2003, 59, 1117-1123.	2.5	10
126	C-Cadherin Ectodomain Structure and Implications for Cell Adhesion Mechanisms. Science, 2002, 296, 1308-1313.	12.6	616

#	Article	IF	Citations
127	G-Protein Signaling Through Tubby Proteins. Science, 2001, 292, 2041-2050.	12.6	352
128	Screening for phasing atoms in protein crystallography. Structure, 2000, 8, R143-R149.	3.3	77
129	Purification, crystallization and initial X-ray analysis of the C1subunit of the astaxanthin protein, V600,of the chondrophoreVelella velella. Acta Crystallographica Section D: Biological Crystallography, 1999, 55, 266-268.	2.5	1
130	Bound-solvent structures for microgravity-, ground control-, gel- and microbatch-grown hen egg-white lysozyme crystals at 1.8 Å... resolution. Acta Crystallographica Section D: Biological Crystallography, 1999, 55, 745-752.	2.5	45